Epirubicin, Cisplatin, and 5-Fluorouracil for Gastro-Oesophageal Cancer
Author Information
Author(s): AA Melcher, D Mort, TS Maughan
Primary Institution: Velindre Hospital
Hypothesis
Can neoadjuvant chemotherapy with ECF improve surgical outcomes in gastro-oesophageal cancer?
Conclusion
Neoadjuvant ECF chemotherapy showed a 56% response rate but did not achieve complete pathological responses.
Supporting Evidence
- 62% of assessable patients had symptomatic improvement on chemotherapy.
- 56% of patients showed objective evidence of tumour response.
- 67% of patients proceeded to surgery after chemotherapy.
Takeaway
Doctors used a special medicine to help patients with stomach and esophagus cancer before surgery, and it helped some feel better, but it didn't completely remove the cancer in any cases.
Methodology
Patients received ECF chemotherapy every 3 weeks for four cycles, followed by assessment for surgery.
Potential Biases
Potential misclassification of resectability based on initial assessments.
Limitations
Accurate staging of tumours was challenging, and the study had a small sample size.
Participant Demographics
{"male":22,"female":5,"mean_age":54,"age_range":"29-71"}
Statistical Information
Confidence Interval
95% confidence interval 58-100% for three-year survival in patients achieving complete resection.
Want to read the original?
Access the complete publication on the publisher's website